Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 846 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in... October 22, 2025 EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate February 20, 2026 EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin February 14, 2025 First Global Estimates of Cervical Cancer Attributable to HIV November 30, 2020 Load more HOT NEWS Hospice Nurse Fired from Job After Being Diagnosed with Breast Cancer ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March An Abnormal Baseline Geriatric 8 Screening Tool Score Strongly Associates with... EMA Recommends Granting a Marketing Authorisation for Vimseltinib
